Compare MNMD & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNMD | SCL |
|---|---|---|
| Founded | 2019 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | MNMD | SCL |
|---|---|---|
| Price | $14.72 | $50.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $30.33 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 154.8K |
| Earning Date | 11-06-2025 | 02-18-2026 |
| Dividend Yield | N/A | ★ 3.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.98 |
| Revenue | N/A | ★ $2,303,837,000.00 |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | N/A | $8.14 |
| P/E Ratio | ★ N/A | $25.28 |
| Revenue Growth | N/A | ★ 5.35 |
| 52 Week Low | $4.70 | $41.82 |
| 52 Week High | $14.81 | $65.89 |
| Indicator | MNMD | SCL |
|---|---|---|
| Relative Strength Index (RSI) | 67.62 | 73.52 |
| Support Level | $13.06 | $46.70 |
| Resistance Level | $14.81 | $47.77 |
| Average True Range (ATR) | 0.84 | 1.13 |
| MACD | 0.11 | 0.23 |
| Stochastic Oscillator | 82.03 | 86.87 |
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.